NCT04953078View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 11, 2021

Primary Completion Date

December 2, 2021

Study Completion Date

November 4, 2022

Conditions
Coronavirus
Interventions
BIOLOGICAL

Baiya SARS-CoV-2 Vax 1

Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Trial Locations (2)

10330

Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok

Queen Saovabha Memorial Institute, Bangkok

All Listed Sponsors
collaborator

National Vaccine Institute, Thailand

OTHER

lead

Baiya Phytopharm Co., Ltd.

INDUSTRY

NCT04953078 - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 | Biotech Hunter | Biotech Hunter